Shares of Dr Reddy's Laboratories ended higher by 9.75 per cent on the BSE as the California-based pharma firm Vivus Inc and Dr.Reddy’s Laboratories have entered into a settlement agreement resolving a patent litigation pertaining to Qsymia (phentermine and topiramate extended-release) weight management capsules.
The agreement permits Dr. Reddy’s to begin selling a generic version of Qsymia on June 1, 2025 or earlier under certain circumstances. In the event of a launch earlier than June 1, 2025, Vivus will receive a royalty on sales of the generic version of Qsymia.
The settlement with Dr. Reddy’s concludes all patent litigation brought by Vivus against generic pharmaceutical companies that had filed ANDAs seeking approval to market generic versions of Qsymia.
In a press release, Vivus said the litigation was pending in the US District Court for the District of New Jersey since 2015 and resulted from the submission of an Abbreviated New Drug Application (ANDA) to the USFDA seeking approval to market generic versions of Qsymia.